Inhibitors of the menin-MLL interaction
US10683302B2 · kind B2 · utility
6Cited by
0References
28Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 8, 2017 |
| Grant date | Jun 16, 2020 |
| Priority date | — |
| Expiry date | Jun 8, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.